Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$2.68
-$0.14(-7.65%)
At close: 4:00 PM EST
$2.68
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)2.05M
Market Cap
$806.24M
Enterprise Value$1.13B
Total Cash (Recent Filing)$271.73M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding141,545,440
10 Day Avg. Volume1,651,285
30 Day Avg. Volume2,052,554
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue1.52K
Enterprise Value/Gross Profit-1.73K
Enterprise Value/Ebitda-7.55
Forecast
1Y Price Target
$4.67Price Target Upside74.25% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$430.17K
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMore than half of the patients needed for the accelerated approval analysis of PROACT 1 have been enrolled.
Financial StabilityProKidney Corp ended the quarter with cash and equivalents of $294.7 million, supporting its operations into mid-2027.
Regulatory ProgressFDA has confirmed that PROACT 1 can also serve as the confirmatory trial for rilparencel.
Bears Say
Clinical RiskAnalyst heavily risk adjusts Phase 3 success due to the absence of a sham and a small representative patient population in previous studies.
Market ConcernsAnalyst maintains an Underperform rating and $1 price objective due to concerns around trial risk and a potentially niche end-market.
Valuation ConcernsReiterate Neutral rating on PROK shares based on valuation and potential of rilparencel balanced with the need for more de-risking on biology and clinical aspects.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $806.24M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is May 08, 2026 which is in 175 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.144 by $0.014.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ProKidney have?
ProKidney has 141,545,440 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.144. Following the earnings report the stock price went up 5.804%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.67 (74.25% Upside)
$4.67 (74.25% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
ProKidney
ProKidney (PROK) is a biotechnology company focused on the development of therapies targeting chronic kidney disease (CKD). Operating within the healthcare and biotechnology sectors, ProKidney is dedicated to pioneering innovative cellular therapies that aim to improve kidney function and provide alternative treatment options for patients with CKD. The company's core product is its proprietary Renal Autologous Cell Therapy (REACT), which is designed to harness a patient's own cells to regenerate kidney tissue and restore kidney function.
PROK Stock 12 Month Forecast
Average Price Target
$4.67
▲(74.25% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
82.51% Insiders
0.17% Mutual Funds
0.05% Other Institutional Investors
16.88% Public Companies and
Individual Investors